Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Biosynex S.A. specializes in the development, manufacture, and worldwide distribution of rapid diagnostic solutions. Their extensive product line includes a variety of quick diagnostic assays, immunoblots, molecular biology tools, and point-of-care devices. These offerings are vital for screening, diagnosis, and prevention across numerous medical fields, such as bacteriology, parasitology, mycology, virology, biochemistry, oncology, and women's health, alongside specific COVID-19 tests and related instruments. Additionally, Biosynex provides consumer products like self-testing kits, personal health monitoring equipment (including thermometers and blood pressure monitors), and a selection of oral care and medical aid supplies. The company serves a diverse client base, including biological and medical analysis laboratories, hospitals, pharmacies, and large retail outlets like hypermarkets and supermarkets. Founded in 1993, Biosynex S.A. is headquartered in Illkirch-Graffenstaden, France.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is neutral on EV/EBITDA.